445 related articles for article (PubMed ID: 32328845)
1. Advances in the Treatment of Cardiac Amyloidosis.
Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Amyloidosis Treatment.
Stern LK; Patel J
Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
[TBL] [Abstract][Full Text] [Related]
4. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Care of Patients with Cardiac Amyloidosis.
Itzhaki Ben Zadok O; Kornowski R
Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
Kittleson MM; Maurer MS; Ambardekar AV; Bullock-Palmer RP; Chang PP; Eisen HJ; Nair AP; Nativi-Nicolau J; Ruberg FL;
Circulation; 2020 Jul; 142(1):e7-e22. PubMed ID: 32476490
[TBL] [Abstract][Full Text] [Related]
9. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
10. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
[TBL] [Abstract][Full Text] [Related]
11. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
12. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
Brito D; Albrecht FC; de Arenaza DP; Bart N; Better N; Carvajal-Juarez I; Conceição I; Damy T; Dorbala S; Fidalgo JC; Garcia-Pavia P; Ge J; Gillmore JD; Grzybowski J; Obici L; Piñero D; Rapezzi C; Ueda M; Pinto FJ
Glob Heart; 2023; 18(1):59. PubMed ID: 37901600
[TBL] [Abstract][Full Text] [Related]
13. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
Griffin JM; Maurer MS
Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy.
Capustin M; Frishman WH
Cardiol Rev; 2021 Sep-Oct 01; 29(5):263-273. PubMed ID: 34397539
[TBL] [Abstract][Full Text] [Related]
17. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.
Ioannou A; Fontana M; Gillmore JD
Heart Int; 2023; 17(1):27-35. PubMed ID: 37456349
[TBL] [Abstract][Full Text] [Related]
18. Illustrative review of cardiac amyloidosis by multimodality imaging.
Tanaka H
Heart Fail Rev; 2023 Jan; 28(1):113-122. PubMed ID: 35474404
[TBL] [Abstract][Full Text] [Related]
19. Amyloidosis in Heart Failure.
Ihne S; Morbach C; Obici L; Palladini G; Störk S
Curr Heart Fail Rep; 2019 Dec; 16(6):285-303. PubMed ID: 31782077
[TBL] [Abstract][Full Text] [Related]
20. Heart of the Matter: Decoding the Underdiagnosed Cardiac Amyloidosis.
Kaiser ME; Lewis TJ
Cureus; 2023 Dec; 15(12):e50527. PubMed ID: 38098740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
